Chronic urticaria: new management options

被引:20
|
作者
Greenberger, Paul A. [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy Immunol, 676 N St Clair St,14108, Chicago, IL 60611 USA
来源
关键词
Urticaria; Chronic; Vasculitis; Antihistamine; H-1; receptor; Omalizumab; Immunosuppressive;
D O I
10.1186/1939-4551-7-31
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Chronic urticaria is defined as episodic or daily hives lasting for at least 6 weeks and impairs quality of life. Two main subtypes include chronic idiopathic (spontaneous) urticaria and inducible (physical) urticaria, but some patients have urticarial vasculitis. "Autoimmune chronic urticaria" implies the presence of histamine releasing or mast cell activating autoantibodies to IgE or FceRI, the high affinity receptor on mast cells and basophils. In patients not readily controlled with labeled dosages of second generation H1 receptor antagonists (antihistamines), there is evidence for reduction of urticaria using up to 4 fold increases in labeled dosages. The biologic modifier, omalizumab, helps to reduce lesions of chronic urticaria within 1-2 weeks.
引用
收藏
页数:6
相关论文
共 50 条